SPARC announces results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson's Disease

Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced results of interim analysis from the PROSEEK study, a global, randomised, double blind, placebo-controlled Phase 2 study in patients with Early Parkinson's Disease. PROSEEK compared two doses of Vodobatinib with placebo and enrolled a total of 513 patients from US, Europe and India.

The interim analysis was based on data from 442 patients who completed 40 weeks treatment in Part I of the study. The study failed to demonstrate superiority of Vodobatinib in the prespecified primary endpoint of change in MDS-UPDRS Part III total score as compared to placebo.

SPARC has reviewed the data and determined that the study has not shown evidence of treatment benefit in patients receiving Vodobatinib, and consequently decided to close the study. SPARC plans to complete the full analysis of clinical outcomes and correlative biomarker data in the coming months.

Anil Raghavan, CEO of SPARC commented, "While the interim analysis results were not what we aspired for our patients, the findings from this study will significantly contribute towards expanding the understanding of the role of c-Abl kinase in alpha synucleinopathies. Our gratitude extends to all those who played a role in the PROSEEK study, particularly the patients and their caregivers, researchers, and our dedicated team that worked relentlessly on the study."

Shares of Sun Pharma Advanced Research Company Limited was last trading in BSE at Rs. 431.10 as compared to the previous close of Rs. 453.75. The total number of shares traded during the day was 16914 in over 184 trades.

The stock hit an intraday high of Rs. 431.10 and intraday low of 431.10. The net turnover during the day was Rs. 7291625.00.

Source : Equity Bulls

Keywords

SunPharmaAdvancedResearchCompany INE232I01014 SPARC Pharmaceuticals PROSEEKStudy EarlyParkinsonsDisease